US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Obesity: market research reports

Weight loss and diet management is a challenge for millions of people around the world. Globally, more than 1 billion people are above an ideal weight. In addition to the negative social effects being overweight has on an individual, the health effects can be deadly. The affects weight has on life-threatening or life-altering disease are devastating.
Diseases such as diabetes, heart disease, and cancer all have links to being overweight or obese.

Increasing education efforts, accessible weight management plans and foods, and a growing desire to be physically desirable have fueled this market in more recent years. More than 100 million people in the United States are actively involved in a weight loss or weight management plan at any one time throughout the year. This suggests a demand for products and services which will continue for years to come.

The definitions or measurement characteristics for overweight and obesity have varied over time. The varied definitions affect prevalence statistics and make it difficult to compare data from different studies. The prevalence of overweight and obesity is commonly assessed by using body mass index (BMI). A BMI over 25 kg/m2 is defined as overweight, and a BMI of over 30 kg/m2 as obese. These markers provide the common benchmarks for assessment, but the risks of disease in all populations can increase progressively from lower BMI levels.

According to the World Health Organization, adult mean BMI levels of 22-23 kg.m2 are found in Africa and Asia, while levels of 25-27 kg.m2 are prevalent across North America, Europe, and in some Latin American, North African and Pacific Island countries. BMI increases among middle-aged elderly people, who are at the greatest risk of health complications. In countries undergoing nutrition transition, overnutrition often coexists with undernutrition. People with a BMI below 18.5 kg/m2 tend to be underweight.

RSS Feeds

Obesity market research reports and industry analysis

< prev 1    3  4  5  6  7  
Obesity Partnering 2009-2014
2/1/2014 | published by: Current Partnering
... by value Deals listed by company A-Z, industry sector, stage of development, technology type Obesity Partnering 2009-2014 provides understanding and access to the obesity partnering deals and agreements entered into by the worlds leading healthcare ...  |  read more...
$995.00
Worksite Weight Loss Programs: A Market Analysis
12/1/2013 | published by: Marketdata Enterprises Inc.
... a flat overall weight loss market, as employers get more serious about reducing health insurance claims related to obesity. The Affordable Care Act is likely to spur more demand for these programs as well. Obesity-related ...  |  read more...
$2,197.00
Health and Wellness in Australia
11/19/2013 | published by: Euromonitor International
... satiety to avoid snacking on empty calories. The strong performance of the organic, food intolerance and fortified/functional categories demonstrated that consumers continue to be better informed regarding their dietary requirements and strive to achieve a ...  |  read more...
$1,900.00
Bariatric Surgery: Global Markets for Services and Devices
11/1/2013 | published by: BCC Research
... almost $1.9 billion by 2018, with a compound annual growth rate (CAGR) of 9.6% between 2013 and 2018. This report provides: An overview of the global market for services and devices in the bariatric surgery ...  |  read more...
$6,650.00
Physician Views: What opportunity for Novo Nordisk's Victoza in obesity?
11/1/2013 | published by: FirstWord
... approval of Victoza (its GLP-1 anti-diabetic) for the treatment of obesity. Most recent Phase III data – published in May – supports a consensus view that Victoza will be filed for obesity and stands a ...  |  read more...
$645.00
PharmaPoint: Obesity - Japan Drug Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. ...  |  read more...
$4,995.00
PharmaPoint: Obesity - Canada Drug Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. ...  |  read more...
$4,995.00
PharmaPoint: Obesity - Current and Future Players
10/31/2013 | published by: GlobalData
... the companies in the rapidly growing obesity market. The report identifies and analyses the key companies shaping and driving the global obesity market. The report provides insight into the competitive obesity landscape, including new companies ...  |  read more...
$2,995.00
Belviq (Obesity) - Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this ...  |  read more...
$3,495.00
Victoza (Obesity) - Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this ...  |  read more...
$3,495.00
Velneperit (Obesity) - Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this ...  |  read more...
$3,495.00
Qsymia (Obesity) - Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this ...  |  read more...
$3,495.00
PharmaPoint: Obesity - UK Drug Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. ...  |  read more...
$4,995.00
PharmaPoint: Obesity - Germany Drug Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. ...  |  read more...
$4,995.00
Oblean (Obesity) - Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this ...  |  read more...
$3,495.00
PharmaPoint: Obesity - Italy Drug Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. ...  |  read more...
$4,995.00
Contrave (Obesity) - Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this ...  |  read more...
$3,495.00
Empatic (Obesity) - Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this ...  |  read more...
$3,495.00
PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. ...  |  read more...
$9,995.00
PharmaPoint: Obesity - US Drug Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. ...  |  read more...
$4,995.00
PharmaPoint: Obesity - France Drug Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. ...  |  read more...
$4,995.00
PharmaPoint: Obesity - Spain Drug Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. ...  |  read more...
$4,995.00
Xenical (Obesity) - Forecast and Market Analysis to 2022
10/31/2013 | published by: GlobalData
... visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this ...  |  read more...
$3,495.00
Disease and Therapy Review: Obesity
10/1/2013 | published by: Timely Data Resources, Inc.
... countries worldwide, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the obesity market, as well as sales of leading drugs and therapies are provided.  |  read more...
$995.00
Orthopaedics: Market Prospects & Global Competition
9/30/2013 | published by: Espicom Healthcare Intelligence
... take stock of the opportunities and challenges that lie ahead. The orthopaedic industry has been under intense pressure since the global economic downturn, and has struggled to achieve growth amid tough market conditions. Additionally, the ...  |  read more...
$1,390.00
< prev 1    3  4  5  6  7  
 
Our Clients